February 1, 2023
1 minute read
Prothena Corp. has reported positive topline results from a Phase 1 single escalating dose trial of PRX005, an investigational tri-epitope antibody for the treatment of Alzheimer’s disease.
According to the company’s press release, PRX005 binds with high affinity to the R1, R2 and R3 repeats within the microtubule binding region (MTBR) of tau and targets the 3R and 4R isoforms.
Prothena conducted a randomized, placebo-controlled trial in 19 healthy volunteers enrolled in three PRX005 dose-level cohorts: low, medium and high doses. Participants received her single IV dose of study drug or placebo and were monitored for 2 months.
Results showed that all three dose levels were generally safe and well-tolerated, with a dose-proportional increase in plasma drug concentrations of PRX005. Not.
“We developed PRX005, which uniquely targets a key region within the MTBR of tau, reducing pathogenic tau uptake into neurons, which is similarly achieved with antibodies targeting other regions of tau. It’s an attribute that couldn’t be done.” Dr. Gene Kinney, Prothena’s president and CEO said in the release: “These pivotal phase 1 data, along with scientific evidence suggesting that tau proliferation may be mediated by her MTBR-tau seeds, highlight his PRX005’s potential in treating Alzheimer’s disease. doing.”
The company is working with Bristol-Myers Squibb to develop PRX005 and expects to announce the results of its ongoing Phase 1 multiple escalating-dose study in patients with Alzheimer’s disease in the second half of 2023, the release said. says.
